Table 2.
Correlation between preoperative fibrinogen concentration and clinicopathological characteristics in pancreatic ductal adenocarcinoma patients undergoing radical R0 resection, n (%)
| Characteristics |
Preoperative fibrinogen concentration
|
P value | |
|
> 3.31 g/L (n = 141)
|
≤ 3.31 g/L (n = 141)
|
||
| Age (yr) | 0.812 | ||
| > 60 | 72 (25.5) | 74 (26.2) | |
| ≤ 60 | 69 (24.5) | 67 (23.8) | |
| Sex | 0.283 | ||
| Male | 71 (25.2) | 80 (28.4) | |
| Female | 70 (24.8) | 61 (21.6) | |
| Blood type | 0.565 | ||
| A | 39 (13.8) | 48 (17.0) | |
| B | 51 (18.1) | 42 (14.9) | |
| AB | 10 (3.5) | 12 (4.3) | |
| O | 41 (14.5) | 39 (13.8) | |
| Diabetes | 0.357 | ||
| Absent | 97 (34.4) | 104 (36.9) | |
| Present | 44 (15.6) | 37 (13.1) | |
| Smoking status | 0.889 | ||
| Absent | 107 (37.9) | 108 (38.3) | |
| Present | 34 (12.1) | 33 (11.7) | |
| Alcohol consumption | 0.263 | ||
| Absent | 121 (42.9) | 114 (40.4) | |
| Present | 20 (7.1) | 27 (9.6) | |
| Family history of cancer | 0.356 | ||
| Absent | 137 (48.6) | 134 (47.5) | |
| Present | 4 (1.4) | 7 (2.5) | |
| Clinical symptoms | < 0.001 | ||
| Absent | 15 (5.3) | 42 (14.9) | |
| Present | 126 (44.7) | 99 (35.1) | |
| Open surgery approach | < 0.001 | ||
| Pancreaticoduodenectomy | 80 (28.4) | 50 (17.7) | |
| Distal pancreatectomy with splenectomy | 61 (21.6) | 91 (32.3) | |
| Tumor location | < 0.001 | ||
| Head and neck | 80 (28.4) | 50 (17.7) | |
| Body and tail | 61 (21.6) | 91 (32.3) | |
| Degree of differentiation | 0.079 | ||
| Well | 20 (7.1) | 14 (5.0) | |
| Moderately | 111 (39.4) | 106 (37.6) | |
| Poorly | 10 (3.5) | 21 (7.4) | |
| Lymphovascular invasion | 0.233 | ||
| Absent | 97 (34.4) | 106 (37.6) | |
| Present | 44 (15.6) | 35 (12.4) | |
| Perineural invasion | 0.054 | ||
| Absent | 28 (9.9) | 42 (14.9) | |
| Present | 113 (40.1) | 99 (35.1) | |
| Capsular invasion | 0.271 | ||
| Absent | 21 (7.4) | 28 (9.9) | |
| Present | 120 (42.6) | 113 (40.1) | |
| Maximal tumor diameter (cm) | 1.000 | ||
| > 4 | 44 (15.6) | 44 (15.6) | |
| ≤ 4 | 97 (34.4) | 97 (34.4) | |
| T stage | 0.991 | ||
| T1 | 17 (6.0) | 17 (6.0) | |
| T2 | 80 (28.4) | 79 (28.0) | |
| T3 | 44 (15.6) | 45 (16.0) | |
| Lymph node metastasis | 0.718 | ||
| Absent | 82 (29.1) | 79 (28.0) | |
| Present | 59 (20.9) | 62 (22.0) | |
| N stage | 0.110 | ||
| N0 | 82 (29.1) | 79 (28.0) | |
| N1 | 40 (14.2) | 52 (18.4) | |
| N2 | 19 (6.7) | 10 (3.5) | |
| TNM stage | 0.099 | ||
| IA | 8 (2.8) | 12 (4.3) | |
| IB | 44 (15.6) | 48 (17.0) | |
| IIA | 30 (10.6) | 19 (6.7) | |
| IIB | 40 (14.2) | 52 (18.4) | |
| III | 19 (6.7) | 10 (3.5) | |
| Preoperative CA19-9 level (U/mL) | 0.023 | ||
| > 336.4 | 47 (16.7) | 30 (10.6) | |
| ≤ 336.4 | 94 (33.3) | 111 (39.4) | |
| Preoperative D-Dimer concentration (g/L) | 0.040 | ||
| > 0.53 | 67 (23.8) | 50 (17.7) | |
| ≤ 0.53 | 74 (26.2) | 91 (32.3) | |
| Adjuvant therapy | 0.631 | ||
| Absent | 64 (22.7) | 60 (21.3) | |
| Present | 77 (27.3) | 81 (28.7) | |